Prestige Wealth Management Group LLC Acquires 403 Shares of Bristol-Myers Squibb (NYSE:BMY)

Prestige Wealth Management Group LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,778 shares of the biopharmaceutical company’s stock after acquiring an additional 403 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Bristol-Myers Squibb were worth $1,628,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Signature Estate & Investment Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 46.6% during the 4th quarter. Signature Estate & Investment Advisors LLC now owns 8,724 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 2,775 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in Bristol-Myers Squibb by 12.2% in the 4th quarter. Zions Bancorporation N.A. now owns 188,331 shares of the biopharmaceutical company’s stock valued at $10,652,000 after acquiring an additional 20,480 shares during the period. GQG Partners LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $2,990,000. Modern Wealth Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 36.4% during the fourth quarter. Modern Wealth Management LLC now owns 17,398 shares of the biopharmaceutical company’s stock worth $966,000 after acquiring an additional 4,647 shares during the period. Finally, CoreFirst Bank & Trust acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $377,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on BMY shares. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Bank of America reissued a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Truist Financial upped their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Citigroup lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Cantor Fitzgerald raised their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Trading Up 0.0 %

Shares of BMY stock opened at $61.09 on Tuesday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The stock’s fifty day moving average price is $58.29 and its two-hundred day moving average price is $56.05. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $123.98 billion, a PE ratio of -13.82, a P/E/G ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.06%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Insider Activity

In related news, EVP Samit Hirawat acquired 1,823 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.